Find similar content

Source channel @githubtrending · Post #15071 · Aug 18

#typescript#agent#agentic_ai#agents#ai#ai_agents#ai_tools#anthropic#automation#bytebot#computer_use#computer_use_agent#cua#desktop#desktop_automation#docker#gemini#llm#mcp#openai Bytebot is an open-source AI desktop agent that acts like a virtual employee with its own computer, able to use real applications, browse websites, handle passwords, and process documents automatically. You just describe tasks in plain English, and Bytebot completes them by clicking, typing, downloading files, organizing data, and running complex workflows across multiple programs. It runs locally on your own infrastructure, ensuring privacy and full control, and supports many AI models. This helps you save time by automating repetitive or complex tasks without scripting, improving efficiency and accuracy in business, research, or development work. https://github.com/bytebot-ai/bytebot

Hashtags

#typescript #agent #agentic_ai #agents #ai #ai_agents #ai_tools #anthropic #automation #bytebot #computer_use #computer_use_agent #cua #desktop #desktop_automation #docker #gemini #llm #mcp #openai

Results

2 similar posts found

Search: #drugdevelopment

当前筛选 #drugdevelopment清除筛选

Crypto M - Crypto News

@CryptoM · Post #64470 · 04/09/2026, 01:45 AM

Find similar View

🚀 Hong Kong's Innovative Drug Sector Gains Momentum Hong Kong's innovative drug sector is experiencing a surge, with several companies showing significant gains. According to Jin10, Ascletis Pharma (01672.HK) saw an increase of over 3%, while Hansoh Pharmaceutical (03692.HK) rose by more than 2%. Other companies such as WuXi AppTec (02359.HK) and Sihuan Pharmaceutical (00460.HK) also followed suit with upward trends. #HongKong#Pharmaceuticals#Biotech#Innovation#StockMarket#Healthcare#DrugDevelopment

Hashtags

#hongkong #pharmaceuticals #biotech #innovation #stockmarket #healthcare #drugdevelopment

Venture Village Wall 🦄

@venturevillagewall · Post #3642 · 12/21/2024, 10:23 AM

Find similar View

PeproMene Bio Secures $11M Round PeproMene Bio, Inc., a clinical-stage biotech firm based in Irvine, CA, has successfully raised $11 million in funding. The investment round closed on December 18, 2024, focusing on innovative therapies targeting cancers and immune disorders. More info: PeproMene Bio #Biotech#Funding#Cancer#ImmuneDisorders#California#ClinicalStage#Therapies#Investment#Healthcare#Innovation#PeproMeneBio#Pharmaceuticals#MedicalResearch#DrugDevelopment

Hashtags

#biotech #funding #cancer #immunedisorders #california #clinicalstage #therapies #investment #healthcare #innovation #pepromenebio #pharmaceuticals #medicalresearch #drugdevelopment